non-small cell lung cancer

Verastem takes on debt to get RAS tumor program to finish line
Fierce Biotech
Mon, 03/28/22 - 10:10 am
Verastem
ovarian cancer
non-small cell lung cancer
funding
After price deal, Takeda's lung cancer drug Exkivity wins UK green light ahead of J&J rival
Fierce Pharma
Mon, 03/21/22 - 10:33 pm
Takeda
JNJ
Exkivity
non-small cell lung cancer
UK
Merck fights back against Roche in adjuvant lung cancer therapy
Pharmaforum
Fri, 03/18/22 - 10:54 am
Merck
Keytruda
non-small cell lung cancer
clinical trials
Roche
Tecentriq
Bristol Myers' Opdivo steps in FDA fast lane for potential first-in-class nod in pre-surgery lung cancer
Fierce Pharma
Mon, 02/28/22 - 11:32 am
Bristol Myers Squibb
FDA
Opdivo
priority review
non-small cell lung cancer
Amgen Snags Another Approval for This Promising Cancer Drug
Motley Fool
Wed, 02/16/22 - 10:48 am
Amgen
Japan
Lumakras
non-small cell lung cancer
advanced non-small cell lung cancer
Amgen Wins Another Key Approval for This Potential Blockbuster Cancer Drug
Motley Fool
Thu, 01/27/22 - 11:36 pm
Amgen
Europe
Lumykras
non-small cell lung cancer
Regeneron announces FDA acceptance for sBLA review of Libtayo with chemotherapy for NSCLC
Pharmaceutical Business Review
Thu, 01/20/22 - 11:00 am
Regeneron
FDA
Libtayo
non-small cell lung cancer
Chasing Roche, Merck unveils adjuvant lung cancer data for Keytruda
Pharmaforum
Tue, 01/11/22 - 11:28 am
Merck
Roche
Keytruda
clinical trials
non-small cell lung cancer
Tecentriq
FDA grants breakthrough designation to AbbVie’s Teliso-V for NSCLC treatment
Pharmaceutical Business Review
Wed, 01/5/22 - 10:33 am
FDA
AbbVie
Teliso-V
telisotuzumab vedotin
non-small cell lung cancer
Good news for Lilly as sintilimab hits the spot in lung cancer again
Pharmaforum
Tue, 10/19/21 - 10:47 am
Eli Lilly
China
Innovent
sintilimab
non-squamous non-small cell lung cancer
non-small cell lung cancer
Roche scores adjuvant lung cancer approval for Tecentriq
Pharmaforum
Mon, 10/18/21 - 11:00 am
Roche
Tecentriq
FDA
non-small cell lung cancer
Roche's Tecentriq crosses the finish line first in adjuvant lung cancer, potentially kicking off gold rush
Endpoints
Fri, 10/15/21 - 10:37 pm
Roche
Tecentriq
non-small cell lung cancer
FDA
Mirati, Sanofi join forces in lung cancer with a KRAS-SHP2 combo approach
Fierce Biotech
Fri, 10/8/21 - 10:34 am
Sanofi
Mirati Therapeutics
adagrasib
non-small cell lung cancer
ESMO 2021 – Astra coasts towards a new lung cancer combo
EP Vantage
Mon, 09/20/21 - 10:54 pm
ESMO
AstraZeneca
Imfinzi
oleclumab
Innate Pharma
non-small cell lung cancer
ESMO21: Libtayo extends survival in first-line NSCLC, challenging Keytruda
Pharmaforum
Mon, 09/20/21 - 11:07 am
Sanofi
Regeneron
Libtayo
ESMO
non-small cell lung cancer
Merck
Keytruda
J&J hunts for a Rybrevant label add just months after rare lung cancer approval
Endpoints
Thu, 08/19/21 - 11:16 am
JNJ
Rybrevant
non-small cell lung cancer
Coherus Bio climbs on positive toripalimab combo results in late-stage lung cancer study
Seeking Alpha
Thu, 08/19/21 - 11:00 am
Coherus Biosciences
Shanghai Junshi Biosciences
clinical trials
toripalimab
non-small cell lung cancer
Innovent - Eli Lilly's Sintilimab Combo Shows Sustained Survival Benefit In Lung Cancer Patients
Benzinga
Fri, 08/6/21 - 11:16 am
Innovent Biologics
Eli Lilly
sintilimab
clinical trials
non-small cell lung cancer
#ASCO21: AstraZeneca's PD-1 Imfinzi tacks on 5-year survival data in NSCLC, which it's calling 'unprecedented'
Endpoints
Fri, 06/4/21 - 10:48 am
ASCO 2021
AstraZeneca
non-small cell lung cancer
Imfinzi
Guardant’s Partnership with Janssen Bears Fruit
Medical Devices and Diagnostics Industry
Mon, 05/24/21 - 11:25 pm
Guardant Health
Janssen
liquid biopsies
FDA
Guardant 360 CDx
Rybrevant
non-small cell lung cancer
diagnostics

Pages